$TIVC
Tivic Health Systems, Inc.

2022 Q3 Form 10-Q Financial Statement

#000141057822002554 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $477.0K $528.0K $428.0K
YoY Change 88.54% 97.01% 32.51%
Cost Of Revenue $414.0K $403.0K $358.0K
YoY Change 37.09% 33.89% 18.94%
Gross Profit $63.00K $125.0K $70.00K
YoY Change -228.57% -478.79% 218.18%
Gross Profit Margin 13.21% 23.67% 16.36%
Selling, General & Admin $2.248M $2.646M $1.910M
YoY Change 122.79% 218.8% 116.8%
% of Gross Profit 3568.25% 2116.8% 2728.57%
Research & Development $399.0K $497.0K $401.0K
YoY Change 133.33% 158.85% 102.53%
% of Gross Profit 633.33% 397.6% 572.86%
Depreciation & Amortization $3.000K $2.000K $2.000K
YoY Change 50.0% 0.0% 0.0%
% of Gross Profit 4.76% 1.6% 2.86%
Operating Expenses $2.647M $3.143M $2.311M
YoY Change 124.32% 207.53% 114.18%
Operating Profit -$2.584M -$3.018M -$2.241M
YoY Change 110.25% 186.07% 112.02%
Interest Expense $1.000K $0.00 $0.00
YoY Change -100.09% -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $1.000K
YoY Change -100.0% -100.0% -100.33%
Pretax Income -$2.584M -$3.018M -$2.240M
YoY Change 11.38% 175.87% 65.19%
Income Tax
% Of Pretax Income
Net Earnings -$2.600M -$3.000M -$2.240M
YoY Change 12.07% 174.22% 65.19%
Net Earnings / Revenue -545.07% -568.18% -523.36%
Basic Earnings Per Share -$0.27 -$0.32 -$0.23
Diluted Earnings Per Share -$0.27 -$0.32 -$0.23
COMMON SHARES
Basic Shares Outstanding 9.678M 9.621M 9.715M
Diluted Shares Outstanding 9.678M 9.621M 9.715M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.328M $9.049M $10.80M
YoY Change 646.23% 457.55% 1700.17%
Cash & Equivalents $6.300M $9.000M $10.80M
Short-Term Investments
Other Short-Term Assets $410.0K $398.0K $633.0K
YoY Change 272.73% 306.12% 125.27%
Inventory $761.0K $833.0K $447.0K
Prepaid Expenses
Receivables $95.00K $92.00K $117.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.594M $10.37M $12.00M
YoY Change 443.2% 384.45% 899.0%
LONG-TERM ASSETS
Property, Plant & Equipment $15.00K $13.00K $16.00K
YoY Change 15.38% -13.33% -5.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $34.00K $34.00K $33.00K
YoY Change -94.04% -91.01% 120.0%
Total Long-Term Assets $614.0K $654.0K $696.0K
YoY Change 5.32% 66.41% 2075.0%
TOTAL ASSETS
Total Short-Term Assets $7.594M $10.37M $12.00M
Total Long-Term Assets $614.0K $654.0K $696.0K
Total Assets $8.208M $11.03M $12.69M
YoY Change 314.34% 335.12% 929.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.602M $1.915M $625.0K
YoY Change 23.33% 61.74% -5.87%
Accrued Expenses $421.0K $463.0K $472.0K
YoY Change 32.39% 48.87% 83.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.023M $2.378M $1.097M
YoY Change -63.83% -54.96% -40.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $413.0K $461.0K $504.0K
YoY Change
Total Long-Term Liabilities $413.0K $461.0K $504.0K
YoY Change -81.06% -46.21% -72.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.023M $2.378M $1.097M
Total Long-Term Liabilities $413.0K $461.0K $504.0K
Total Liabilities $2.436M $2.839M $1.601M
YoY Change -68.66% -53.74% -56.55%
SHAREHOLDERS EQUITY
Retained Earnings -$27.40M -$24.80M -$21.80M
YoY Change
Common Stock $1.000K $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.772M $8.187M $11.09M
YoY Change
Total Liabilities & Shareholders Equity $8.208M $11.03M $12.69M
YoY Change 314.34% 335.12% 929.52%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$2.600M -$3.000M -$2.240M
YoY Change 12.07% 174.22% 65.19%
Depreciation, Depletion And Amortization $3.000K $2.000K $2.000K
YoY Change 50.0% 0.0% 0.0%
Cash From Operating Activities -$2.772M -$1.752M -$2.168M
YoY Change 68.61% 222.65% 226.02%
INVESTING ACTIVITIES
Capital Expenditures -$5.000K $0.00 $6.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$5.000K $0.00 -$6.000K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 56.00K 0.000 0.000
YoY Change -93.56% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -2.772M -1.752M -2.168M
Cash From Investing Activities -5.000K 0.000 -6.000K
Cash From Financing Activities 56.00K 0.000 0.000
Net Change In Cash -2.721M -1.752M -2.174M
YoY Change 251.1% -271.26% 389.64%
FREE CASH FLOW
Cash From Operating Activities -$2.772M -$1.752M -$2.168M
Capital Expenditures -$5.000K $0.00 $6.000K
Free Cash Flow -$2.767M -$1.752M -$2.174M
YoY Change 222.65% 226.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9621484
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
163000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9621484
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2374479
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9668100
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2354589
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9715234
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001787740
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 tivc Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2021Q4 tivc Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32046
dei Entity Registrant Name
EntityRegistrantName
Tivic Health Systems, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-4016391
dei Entity Address Address Line1
EntityAddressAddressLine1
25821 Industrial Blvd.,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
dei City Area Code
CityAreaCode
888
dei Local Phone Number
LocalPhoneNumber
276-6888
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
TIVC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9677734
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9049000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12975000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
92000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
92000
CY2022Q2 us-gaap Inventory Net
InventoryNet
833000
CY2021Q4 us-gaap Inventory Net
InventoryNet
429000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
398000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
793000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
10372000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
14289000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
607000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
687000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
34000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
49000
CY2022Q2 us-gaap Assets
Assets
11026000
CY2021Q4 us-gaap Assets
Assets
15036000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1915000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
789000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
293000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
267000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
170000
CY2022Q2 us-gaap Liabilities
Liabilities
2839000
CY2021Q4 us-gaap Liabilities
Liabilities
1764000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2378000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1219000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
461000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
545000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9621484
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9715234
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32990000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32817000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24804000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19546000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
8187000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13272000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11026000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15036000
CY2022Q2 us-gaap Revenues
Revenues
528000
CY2021Q2 us-gaap Revenues
Revenues
268000
us-gaap Revenues
Revenues
956000
us-gaap Revenues
Revenues
591000
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
403000
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
301000
us-gaap Cost Of Revenue
CostOfRevenue
760000
us-gaap Cost Of Revenue
CostOfRevenue
602000
CY2022Q2 us-gaap Gross Profit
GrossProfit
125000
CY2021Q2 us-gaap Gross Profit
GrossProfit
-33000
us-gaap Gross Profit
GrossProfit
196000
us-gaap Gross Profit
GrossProfit
-11000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
497000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
192000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
898000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
390000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1125000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
345000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1809000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
645000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1521000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
485000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2747000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1066000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3143000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
1022000
us-gaap Operating Expenses
OperatingExpenses
5454000
us-gaap Operating Expenses
OperatingExpenses
2101000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3018000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1055000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5258000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2112000
CY2021Q2 us-gaap Interest Expense
InterestExpense
223000
us-gaap Interest Expense
InterestExpense
497000
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
28000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1000
CY2021Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
156000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
158000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-39000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-338000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3018000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1094000
us-gaap Net Income Loss
NetIncomeLoss
-5258000
us-gaap Net Income Loss
NetIncomeLoss
-2450000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9621484
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2374479
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9668100
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2354589
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-1177000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2021Q1 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
-10000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1356000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-2517000
CY2021Q2 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
-8000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1094000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-3603000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13272000
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
-61000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2240000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11093000
CY2022Q2 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
-112000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3018000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
8187000
us-gaap Profit Loss
ProfitLoss
-5258000
us-gaap Profit Loss
ProfitLoss
-2450000
us-gaap Share Based Compensation
ShareBasedCompensation
173000
us-gaap Share Based Compensation
ShareBasedCompensation
18000
us-gaap Depreciation
Depreciation
4000
us-gaap Depreciation
Depreciation
4000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
469000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
80000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-6000
us-gaap Inventory Write Down
InventoryWriteDown
-8000
tivc Gain On Paycheck Protection Program Loan Forgiveness
GainOnPaycheckProtectionProgramLoanForgiveness
157000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
71000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
404000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
42000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-395000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-62000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1126000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
814000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
26000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
160000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-77000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-15000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3920000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1208000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
19000
tivc Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
363000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2163000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1787000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3926000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
579000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12975000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1044000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9049000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1623000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1107000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
177000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3000000.0
us-gaap Net Income Loss
NetIncomeLoss
-5300000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24800000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9000000.0
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate.</p>
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2021Q4 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
82000
CY2022Q2 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
26000
CY2021Q4 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
16000
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk and Other Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and accounts receivable. Cash and cash equivalents include accounts held at one financial institution in the United States. At times, such deposits may be in excess of insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. The Company has not experienced any losses on its deposits of cash and cash equivalents. As of June 30, 2022 and December 31, 2021, the Company had cash and cash equivalents balances exceeding FDIC insured limits by $8.5 million and $12.5 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2022, the Company had two customers whose accounts receivable balances each totaled more than 10% or more of the Company’s total accounts receivable (20% and 17%) compared with two such customers at December 31, 2021 (40% and 28%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended June 30, 2022, the Company had no customer who individually accounted for 10% or more of the Company’s total revenue. For the three months ended June 30, 2021, the Company had two customers who individually accounted for 10% or more of the Company’s total revenue (20% and 24%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the six months ended June 30, 2022, the Company had one customer who individually accounted for 10% or more of the Company’s total revenue (13%) compared with one customer for the six months ended June 30, 2021 (13%).</p>
CY2022Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
8500000
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
12500000
CY2022Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
8744000
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
8744000
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8744000
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
8744000
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
12793000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
12793000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12793000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
12793000
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8700000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12800000
CY2022Q2 tivc Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2021Q4 tivc Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
642000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
281000
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
191000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
148000
CY2022Q2 us-gaap Inventory Gross
InventoryGross
833000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
429000
CY2022Q2 us-gaap Inventory Net
InventoryNet
833000
CY2021Q4 us-gaap Inventory Net
InventoryNet
429000
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
297000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
724000
CY2022Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
15000
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
7000
CY2022Q2 us-gaap Other Assets
OtherAssets
86000
CY2021Q4 us-gaap Other Assets
OtherAssets
62000
CY2022Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
398000
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
793000
CY2022Q2 us-gaap Area Of Land
AreaOfLand
9091
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
51000
us-gaap Operating Lease Cost
OperatingLeaseCost
101000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
6000
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
11000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
9000
CY2022Q2 us-gaap Lease Cost
LeaseCost
57000
CY2021Q2 us-gaap Lease Cost
LeaseCost
3000
us-gaap Lease Cost
LeaseCost
112000
us-gaap Lease Cost
LeaseCost
9000
CY2022Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y3M
CY2022Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.060
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
607220
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
496381
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
50000
us-gaap Operating Lease Payments
OperatingLeasePayments
88000
us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
101000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
206000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
210000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
178000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
695000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
64000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
631000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
93750
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
272680
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
272680
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1285100
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
707250
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2054161
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1587150
CY2022Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
280000
CY2021Q4 tivc Warrants Or Rights Fair Value Assumptions Method Used
WarrantsOrRightsFairValueAssumptionsMethodUsed
Black-Scholes options valuation model
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
328000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021 tivc Percentage Of Number Of Shares Added Each Year
PercentageOfNumberOfSharesAddedEachYear
0.050
CY2021Q4 tivc Percentage Of Number Of Shares Added Each Year
PercentageOfNumberOfSharesAddedEachYear
0.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
607220
CY2021Q4 tivc Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price On Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePriceOnOutstanding
280090
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
696630
tivc Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Grants In Period On Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableGrantsInPeriodOnGross
41674
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
18750
tivc Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableForfeituresInPeriod
18750
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1285100
CY2022Q2 tivc Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price On Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePriceOnOutstanding
303014
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.97
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.68
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
100781
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
7031
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
93750
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
112000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
173000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1557780
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2990909
CY2022Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
10000
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
13000
CY2022Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
5000

Files In Submission

Name View Source Status
0001410578-22-002554-index-headers.html Edgar Link pending
0001410578-22-002554-index.html Edgar Link pending
0001410578-22-002554.txt Edgar Link pending
0001410578-22-002554-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tivc-20220630.xsd Edgar Link pending
tivc-20220630x10q.htm Edgar Link pending
tivc-20220630x10q001.jpg Edgar Link pending
tivc-20220630xex31d1.htm Edgar Link pending
tivc-20220630xex31d2.htm Edgar Link pending
tivc-20220630xex32d1.htm Edgar Link pending
tivc-20220630_lab.xml Edgar Link unprocessable
tivc-20220630_pre.xml Edgar Link unprocessable
tivc-20220630_cal.xml Edgar Link unprocessable
tivc-20220630x10q_htm.xml Edgar Link completed
tivc-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable